ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -25.0% ·
share flow +30.0% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +1 | 15.27M | $1.21B | +7 | −5 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | — |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | — | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | — |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | — | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | — | −3 |
| Q2 2024 | 12 | — | 1.26M | $80.52M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 529.88K | +43.9% | $31.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 529.88K | +43.9% | $31.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Millennium Management ✦ | 529.75K | +130.2% | $31.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 425.23K | +4.2% | $25.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 425.23K | +4.2% | $25.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 245.10K | +56.3% | $14.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 108.62K | +1140.0% | $6.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 15.40K | -12.1% | $919,003 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 9.41K | -78.4% | $561,461 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 9.41K | -78.4% | $561,461 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 9.41K | -78.4% | $561,461 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 9.41K | -78.4% | $561,461 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 6.07K | +3.2% | $363,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 5.71K | -21.9% | $340,420 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Arrowstreet Capital | $592,000 | was 0.0% |
| Gotham Asset Management | $313,879 | was 0.0% |
| Marshall Wace | $253,383 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 276 holders, 23.08M shares, $1.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 500 sh · $37,740
Officer · 3.16K sh · $243,474
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology